New object flying in our solar system? ASU explains
After the news broke, CVHP reached out to the ASU's Department of Physics & Geosciences to find out more information about the sednoid designated as 2023 KQ14.
What is a sednoid?
According to Kenneth Carrell, the Planetarium Director at ASU, the 'sednoid' designation is given to objects with some characteristics similar to a Neptunian object and a potential dwarf planet called Sedna. The International Astronomical Union (IAU) has specific definitions for a 'planet' and a 'dwarf planet' and there are currently only five officially recognized dwarf planets.
'Future observations may result in more objects getting moved into that category, including potentially Sedna,' said Carrell.
How 2023 KQ14 was found?
Carrell told the publication that the discovery of this object was made using the Subaru Telescope which located in Hawaii. This telescope has a diameter of just over 8 meters and is in the top 10 largest telescopes currently in use.
'Interestingly, although this object was 'discovered' recently by the team using the Subaru Telescope, they used archival images from surveys as far back as 2014 to get a better idea of the orbit of the object (they discuss these 'precoveries' in the Methods section of the Nature article),' said Carrell.
He then explained that there are surveys and telescopes being dedicated to discoveries like this, so discovering objects like 2023 KQ14 may be much more common in the near future.
'So, this object could have been discovered years ago if people knew where to look for it,' said Carrell.
More Facts about 2023 KQ14
Carrell said 2023 KQ14 is an object in our Solar System and described it as a Trans-Neptunian object on a highly elliptical orbit. A trans-Neptunian object is a celestial body that orbits the Sun at a greater average distance than Neptune.
He said 2023 KQ14's perihelion, or closest approach to the Sun, is almost 70 times farther from the Sun than Earth, and more than twice as far as Neptune, the most distant planet in our Solar System. In contrast, its aphelion, or farthest distance from the Sun, is more than 400 times the Earth-Sun distance, placing it well beyond the heliopause, the widely recognized boundary between the Solar System and interstellar space.
He also said that 2023 KQ14 is not possible to see with your unaided eye or with amateur telescopes. The apparent magnitude of the object is just over 25, which is more than 50 million times fainter than your eye can detect in the darkest of conditions. He also added that observing objects this faint requires the largest ground-based telescopes or space telescopes.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
25 minutes ago
- Medscape
Claims Data Fail to Accurately Identify MI Types
TOPLINE: Clinical auditing reveals significant misclassification in administrative codes for myocardial infarction (MI), with only 39% of type 1 (T1MI) codes and 72% of type 2 (T2MI) codes for the condition accurately reflecting the true diagnosis, researchers found. Nearly half of patients coded for T1MI had T2MI, whereas 26% of T2MI codes represented myocardial injury. METHODOLOGY: Researchers identified 350 randomly sampled patients with T1MI codes and 350 patients with T2MI codes during inpatient encounters using the International Statistical Classification of Diseases and Related Health Problems-10th Revision. The analysis included patients aged 65 years and older from October 1, 2017, to May 9, 2024, within eight hospitals in the Mass General Brigham system. Using the 4th Universal Definition of MI, the researchers reviewed the clinical encounters to assess evidence of plaque erosion or thrombus vs oxygen demand-supply imbalance. A second physician review was conducted for 146 challenging and 146 nonchallenging cases. TAKEAWAY: Among the 350 patients coded as having had T1MI, clinical adjudication revealed 138 (39%) as correctly diagnosed; 159 (45%) in fact had T2MI, and 35 (10%) had myocardial injury. Of the 350 patients coded as having had T2MI, 251 (72%) were confirmed, four (1%) were found to have T1MI, and 91 (26%) had myocardial injury. A second physician review demonstrated a high degree of agreement with the initial review, with a 94% agreement in nonchallenging cases and 86% in challenging cases. Hospitals equipped with vs without cardiac catheterization laboratories showed significantly lower misclassification rates (43% vs 58%; P = .0298). IN PRACTICE: 'Among individuals assigned a T1MI claims code, nearly one half have T2MI and many others have myocardial injury; fewer than one half have true T1MI,' the researchers reported. 'Our results also confirm and extend previous work showing that among those with T2MI codes, slightly more than one half have true T2MI, with most of the misclassification related to myocardial injury rather than T1MI. This has critically important implications for epidemiology and public policy' related to acute myocardial infarction. SOURCE: The study was led by Andrea Martinez, MD, of the Department of Medicine at Massachusetts General Hospital, Boston. It was published online on July 21 in Journal of the American College of Cardiology. LIMITATIONS: The results may not be generalized to other hospital systems and countries, where patterns of misclassification might differ. The researchers noted external validity assessment across multiple healthcare systems and in countries that have already introduced International Classification of Diseases-11th revision coding would be beneficial. While patterns of misclassification might have changed over time, the analysis was intentionally restricted to the period when codes for both T1MI and T2MI were available. DISCLOSURES: The study received support through a grant to Jason Wasfy from the Massachusetts General Hospital Executive Committee on Research. Individual authors reported receiving other grants and support, including grants from industry. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Digital Trends
25 minutes ago
- Digital Trends
Remember Ingenuity? NASA's proposed Skyfall mission takes it further in stunning video
NASA's incredible Ingenuity helicopter spent nearly three flying across the surface of Mars, becoming the first aircraft to achieve powered, controlled flight on a planet other than Earth. After suffering damage to one of its blades in early 2024, Ingenuity was grounded for good, and now rests on the martian surface as a testament to technological innovation and the triumph of autonomous flight on another planet. In an exciting development, the plucky helicopter has now inspired Skyfall, a mission concept recently unveiled by Virginia-based AeroVironment (AV) and NASA's Jet Propulsion Laboratory (JPL), who worked together to develop the Ingenuity aircraft. As you can see in the video at the top of this page, the Skyfall mission is designed to deploy not one but six helicopters on Mars, each of which would fly off to explore various locations selected by NASA as potential landing spots for the first crewed mission to the red planet, which could take place in the 2030s. The gathered data could also help scientists learn more about Mars, contributing to the expanding database of information collected by other Mars vehicles such as the Perseverance and Curiosity rovers. The video shows the dramatic Skyfall Maneuver, described by AV as 'an innovative entry, descent, and landing technique whereby the six rotorcraft deploy from their entry capsule during its descent through the martian atmosphere.' With the helicopters flying down to the Mars surface under their own power, the Skyfall system would do away with the need for a landing platform, which is one of the most expensive parts of any Mars mission and also carries huge risk. Just like Ingenuity, each helicopter would be capable of operating autonomously, and beam high-resolution imagery back to Earth for analysis, allowing mission planners to select the best possible landing location for the first human mission. 'Skyfall offers a revolutionary new approach to Mars exploration that is faster and more affordable than anything that's come before it,' said William Pomerantz, head of space ventures at AV. 'Thanks to a true partnership between industry and government, we're expanding the unprecedented success of Ingenuity.' Pomerantz added that with six helicopters, 'Skyfall offers a low-cost solution that multiplies the range we would cover, the data we would collect, and the scientific research we would conduct, making humanity's first footprints on Mars meaningfully closer.' With NASA's first human missions in mind and the need to identify an ideal landing area, AV is already working with NASA's JPL in the hope of getting the green light for the mission before working toward a potential 2028 launch.
Yahoo
an hour ago
- Yahoo
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
– Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – SOUTH SAN FRANCISCO, Calif., July 28, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. "Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition." Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. "Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis," said Matt Sause, CEO of Roche Diagnostics. "Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families." Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Pharmaceuticals In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Diagnostics Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm - 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm - 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm - 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm - 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am - 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley About trontinemab Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. About Roche in Alzheimer's Disease With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact: Meghan Hindman (650) 467-6800Advocacy Contact: Jenee Williams (650) 303-2958Investor Contacts: Loren Kalm (650) 225-3217Bruno Eschli +41616875284 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
